Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox.

The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, topping the nearly $4.18 billion consensus estimate of S&P Global Market Intelligence. By comparison, Allergan reported $2.4 billion in net revenue for Q4 2014.

U.S. revenue rose 37.5% to nearly $2.5 billion for the three-month period that ended Dec. 31, the company reported. Botox global sales were about $460 million.

Looking ahead, Allergan CEO Brett Saunders says he sees no regulatory hurdles that would impede the proposed Pfizer-Allergan deal. Pfizer agreed in November to buy Allergan for $160 billion.

“When we put Allergan and Pfizer together, we will create the preeminent biopharmaceutical company in the world. We will be focused on nine or 10 therapeutic areas including aesthetics,” Saunders told Modern Aesthetics in an interview. “They are more complementary, so while we need to approve the process, we don’t expect it to be overly problematic,” he said at the time.